Mon, Dec 22, 2014, 5:03 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

IntelliPharmaCeutics International Inc. Message Board

  • sragonese sragonese Nov 22, 2013 4:59 PM Flag

    For Longs


    You got 3 Analyst covering; 12mil float, and a possible 250% next year growth. IPCI is ready to roll out their product, nothing to do but see how it's received and watch the price go up. That's all there is right now so avoid these asinine shorts claiming total destruction or typical text book pump & dump scenario. Actually, for anyone to short a 12mil float at these prices, and with so many BIOS being bought out, is simply stupid and text book bad investing. Wonder how many shorts got margin calls when it popped to the 5 area. Either way, looking forward to good news and more analyst coverage... Have a great weekend.

    Sentiment: Strong Buy

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • That's what the ignore function is for..

    • Shorts were practically non-existent as of Oct 31, but I suspect a bunch jumped on after the runup. We'll see in a few days. I agree with the rest of your post. IPCI is in transition from development stage to money maker.

    • and what if FDA rejects their products left & right. Remember ARIA or CHTP or DSCO other bio stocks back in the day that did not get the FDA nod as soon as everybody was hoping for.

      FDA approval is the hardest thing in the world to get. So why root for it when it is so hard to get anyway is my motto? Why not root against it when FDA's power is a nice tailwind for you as a short

      Sentiment: Strong Sell

      • 2 Replies to holywallst
      • The first domino of approval has been granted, most of the rest are also generics. What had been a concern to me the past 3 years was why it took so damn long to get a thumbs up or down on their applications. My mistrust was misplaced. It was the FDA that was the problem and still is the hang up on the rest of the approvals of the generics. Focalin ANDA was applied for back in 2007, that's 6 years! I couldn't believe it was taking so long when the average is around 3 years. So it's still a waiting game, but at least now shareholders can wait with more confidence that eventually FDA will approve the other generics. The big money will roll in when Rexista is finally approved, but that is probably at least another 4-5 years away unfortunately.

        Sentiment: Strong Buy

      • That's ridiculous ... The FDA approval essentially validates their approach and the remaining formulations of different strengths is not an issue which is why the FDA already gave them tentative approval ... Do you not read ?

        It detailed further, “The Company's 5, 10, 20 and 40 mg strengths were also tentative FDA approved, subject to the right of another party or parties to 180 days of generic exclusivity from the date of first launch by such parties. Par intends to launch these strengths immediately upon the expiry of those exclusivity periods.”

        Sentiment: Strong Buy

2.31-0.0100(-0.43%)Dec 22 3:59 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.